Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 17558427)

1.

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB.

Nat Rev Microbiol. 2007 Jul;5(7):540-53. Review.

2.

Recent progress towards development of a Shigella vaccine.

Camacho AI, Irache JM, Gamazo C.

Expert Rev Vaccines. 2013 Jan;12(1):43-55. doi: 10.1586/erv.12.135. Review.

PMID:
23256738
3.

Live-attenuated Shigella vaccines.

Venkatesan MM, Ranallo RT.

Expert Rev Vaccines. 2006 Oct;5(5):669-86. Review.

PMID:
17181440
4.

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM.

Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17.

PMID:
21596086
5.

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, Venkatesan M, Hale TL, Isenbarger DW, Sansonetti PJ, Black RE, Baqui AH.

Vaccine. 2011 Feb 1;29(6):1347-54. doi: 10.1016/j.vaccine.2010.10.035. Epub 2010 Oct 30.

PMID:
21040694
6.

Shigella vaccine development: prospective animal models and current status.

Kim YJ, Yeo SG, Park JH, Ko HJ.

Curr Pharm Biotechnol. 2013;14(10):903-12. Review.

PMID:
24372251
7.

Progress and pitfalls in Shigella vaccine research.

Barry EM, Pasetti MF, Sztein MB, Fasano A, Kotloff KL, Levine MM.

Nat Rev Gastroenterol Hepatol. 2013 Apr;10(4):245-55. doi: 10.1038/nrgastro.2013.12. Epub 2013 Feb 19. Review.

8.

Vaccination of children in low-resource countries against Shigella is unlikely to present an undue risk of reactive arthritis.

Gaston JS, Inman RD, Ryan ET, Venkatesan MM, Barry EM, Hale TL, Bourgeois AL, Walker RI.

Vaccine. 2009 Sep 4;27(40):5432-4. doi: 10.1016/j.vaccine.2009.06.107. Epub 2009 Jul 28.

PMID:
19643213
9.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78. Epub 2006 Dec 20.

PMID:
17229494
10.

Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice.

Barman S, Koley H, Nag D, Shinoda S, Nair GB, Takeda Y.

Microbiol Immunol. 2014 Aug;58(8):463-6. doi: 10.1111/1348-0421.12164.

PMID:
24909404
11.

Cross-protection provided by live Shigella mutants lacking major antigens.

Szijártó V, Hunyadi-Gulyás E, Emődy L, Pál T, Nagy G.

Int J Med Microbiol. 2013 May;303(4):167-75. doi: 10.1016/j.ijmm.2013.02.017. Epub 2013 Mar 16.

PMID:
23567193
12.

Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.

Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, Venkatesan MM.

Vaccine. 2012 Jul 20;30(34):5159-71. doi: 10.1016/j.vaccine.2012.05.003. Epub 2012 May 30.

PMID:
22658966
13.

Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DeltaicsA Deltaent Deltafep DeltastxA:HgR oral vaccine SC599 in healthy human adult volunteers.

Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, Johnson J, Liddy H, Cosgrove CA, Allavena P, Mantovani A, Béchet S, Fontaine-Thompson A, Griffin GE, Dupont F, Sansonetti PJ, Lewis DJ.

Vaccine. 2008 Feb 13;26(7):978-87. doi: 10.1016/j.vaccine.2007.11.024. Epub 2007 Dec 3.

PMID:
18207287
14.

Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model.

Barry EM, Wang J, Wu T, Davis T, Levine MM.

Vaccine. 2006 May 1;24(18):3727-34. Epub 2005 Jul 22.

PMID:
16169130
15.

Protective immunity by oral immunization with heat-killed Shigella strains in a guinea pig colitis model.

Barman S, Koley H, Ramamurthy T, Chakrabarti MK, Shinoda S, Nair GB, Takeda Y.

Microbiol Immunol. 2013 Nov;57(11):762-71. doi: 10.1111/1348-0421.12095.

PMID:
24033533
16.

Construction of a multivalent vaccine strain of Shigella flexneri and evaluation of serotype-specific immunity.

Jennison AV, Roberts F, Verma NK.

FEMS Immunol Med Microbiol. 2006 Apr;46(3):444-51.

17.

Shigellosis: the current status of vaccine development.

Kweon MN.

Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Review.

PMID:
18448978
18.

Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?

Phalipon A, Mulard LA, Sansonetti PJ.

Microbes Infect. 2008 Jul;10(9):1057-62. doi: 10.1016/j.micinf.2008.07.016. Epub 2008 Jul 10. Review.

PMID:
18672087
19.

Shigellosis in custodial institutions. 3. Prospective clinical and bacteriologic surveillance of children vaccinated with oral attenuated shigella vaccines.

Levine MM, Gangarosa EJ, Werner M, Morris GK.

J Pediatr. 1974 Jun;84(6):803-6. No abstract available.

PMID:
4596999
20.

Pathogenesis and immunology in shigellosis: applications for vaccine development.

Hale TL, Keren DF.

Curr Top Microbiol Immunol. 1992;180:117-37. Review. No abstract available.

PMID:
1380415
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk